Publicacións en colaboración con investigadores/as de Hospital Universitari Germans Trias i Pujol (15)

2020

  1. A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01)

    Neuro-oncology, Vol. 22, Núm. 12, pp. 1851-1861

2018

  1. Correction to: SEOM clinical guidelines for anaplastic gliomas (2017) (Clinical and Translational Oncology, (2018), 20, 1, (16-21), 10.1007/s12094-017-1762-7)

    Clinical and Translational Oncology

  2. Delay in starting radiotherapy due to neoadjuvant therapy does not worsen survival in unresected glioblastoma patients

    Clinical and Translational Oncology, Vol. 20, Núm. 12, pp. 1529-1537

  3. SEOM clinical guidelines for anaplastic gliomas (2017)

    Clinical and Translational Oncology, Vol. 20, Núm. 1, pp. 16-21

2017

  1. FOTROCAN Delphi consensus statement regarding the prevention and treatment of cancer-associated thrombosis in areas of uncertainty and low quality of evidence

    Clinical and Translational Oncology, Vol. 19, Núm. 8, pp. 997-1009

2016

  1. Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial

    Journal of Neuro-Oncology, Vol. 127, Núm. 3, pp. 569-579

2015

  1. A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma

    Clinical and Translational Oncology, Vol. 17, Núm. 9, pp. 743-750

  2. Updated guidelines for biomarker testing in colorectal carcinoma: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

    Clinical and Translational Oncology, Vol. 17, Núm. 4, pp. 264-273

2014

  1. Efficacy of erlotinib in patients with relapsed gliobastoma multiforme who expressed EGFRVIII and PTEN determined by immunohistochemistry

    Journal of Neuro-Oncology, Vol. 116, Núm. 2, pp. 413-419

  2. Erratum: Efficacy of erlotinib in patients with relapsed gliobastoma multiforme who expressed EGFRVIII and PTEN determined by immunohistochemistry [J Neurooncol, 116, (2014), 413-419, DOI 10.1007/s11060-013-1316-y]

    Journal of Neuro-Oncology

  3. Should we continue temozolomide beyond six cycles in the adjuvant treatment of glioblastoma without an evidence of clinical benefit? A cost analysis based on prescribing patterns in Spain

    Clinical and Translational Oncology, Vol. 16, Núm. 3, pp. 273-279

2012

  1. Guidelines for biomarker testing in colorectal carcinoma (CRC): A national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM)

    Clinical and Translational Oncology, Vol. 14, Núm. 10, pp. 726-739

  2. Recomendación para la determinación de biomarcadores en el carcinoma colorrectal. Consenso Nacional de la Sociedad Española de Anatomía Patológica y de la Sociedad Española de Oncología Médica

    Revista Espanola de Patologia

  3. SEOM guideline for the treatment of malignant glioma

    Clinical and Translational Oncology, Vol. 14, Núm. 7, pp. 545-550

2010

  1. Extended-schedule dose-dense temozolomide in refractory gliomas

    Journal of Neuro-Oncology, Vol. 96, Núm. 3, pp. 417-422